Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study

Ando, Taiki; Fujisawa, Shin; Teshigawara, Haruka; Matsumura, Ayako; Sakuma, Takayuki; Suzuki, Taisei; Teranaka, Hiroshi; Ogusa, Eriko; Ishii, Yoshimi; Miyashita, Kazuho; Takahashi, Hiroyuki; Nakajima, Yuki; Miyazaki, Tatsuya; Hagihara, Maki; Matsumoto, Kenji; Yamazaki, Etsuko; Nakajima, Hitoshi

doi:10.1007/s12185-020-02870-5

Cited by 23 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcopenia, the loss of skeletal muscle mass, is closely related to nutritional status. There are several studies that reported the impact of pretransplant sarcopenia on posttransplant outcomes at autologous or allogeneic HSCT [29][30][31][32][33][34][35]. In one meta-analysis, which included seven retrospective studies, sarcopenia was associated with higher non-relapse mortality and inferior OS in patients underwent HSCT with hematologic malignancies [36].…”

Section: 7%) Cmentioning

confidence: 99%

Lower Body Mass Index and Prognostic Nutritional Index Are Associated with Poor Posttransplant Outcomes in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Yucel,

Vural,

Alhan

et al. 2023

Oncology

View full text Add to dashboard Cite

Background: Pre-transplant inflammatory and nutritional status has not been widely explored in terms of its impact on autologous hematopoietic stem cell transplantation (auto-HSCT) outcomes in lymphoma patients. We aimed to evaluate the impact of body mass index (BMI), prognostic nutri-tional index (PNI), and C-reactive protein to albumin ratio (CAR) on auto-HSCT outcomes. Meth-od: We retrospectively analyzed 87 consecutive lymphoma patients who underwent their first auto-HSCT at the Adult Hematopoietic Stem Cell Transplantation Unit at Akdeniz University Hospital. Result: CAR had no impact on post-transplant outcomes. PNI≤50 was an independent prognostic factor for both shorter progression free survival (PFS) (hazard ratio [HR]=2.43, P = .025) and worse overall survival (OS) (HR=2.93, P = .021), respectively. The 5-year PFS rate was significantly lower in patients with PNI≤50 than in patients with PNI>50 (37.3% vs. 59.9%, P = .003). The 5-year OS rate in patients with PNI≤50 had significantly low when compared with patients who had PNI>50 as well (45.5% vs. 67.2%, P = .011). Patients with BMI<25 had higher 100-day TRM compared with patients with BMI≥25 (14.7% vs 1.9%, P = .020). BMI<25 was an independent prognostic factor associated with shorter PFS and OS (HR=2.98, P = .003, HR=5.06, P < .001, respectively). The 5-year PFS rate was significantly lower in patients with BMI<25 than patients with BMI≥25 (40.2% vs. 53.7%, P = .037). Similarly, the 5-year OS rate in patients with BMI<25 had significant-ly inferior compared to patients with BMI≥25 (42.7% vs. 64.7%, P = .002). Conclusion: Our study confirms that lower BMI and CAR have negative impacts on auto-HSCT outcomes in lymphoma patients. Furthermore, higher BMI should not be considered an obstacle for lymphoma patients who need auto-HSCT, conversely, it could be an advantage for post-transplant outcomes. Keywords: Lymphoma, autologous hematopoietic stem cell transplantation, body mass index, prognostic nutritional index

show abstract

Section: 7%) Cmentioning

confidence: 99%

Lower Body Mass Index and Prognostic Nutritional Index Are Associated with Poor Posttransplant Outcomes in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Yucel,

Vural,

Alhan

et al. 2023

Oncology

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] Sarcopenia is associated with adverse perioperative outcomes (prolonged hospitalization and increased ventilator dependency), longer-term outcomes (delayed growth, reduced survival, increased risk for rehospitalization, organ rejection/graft versus host disease) and delayed gross motor function after Tx. 3,[5][6][7] The cause for this condition is multifactorial; related to malnutrition, malabsorption, medications (corticosteroids/chemo or radiotherapy), altered nutrient utilization, reduced growth, and physical activity (PA). 8 While there is evidence that pediatric Tx recipients may experience significant risk for sarcopenia (>40% of children), 4,5,9 there is limited evidence regarding the potential impact of exercise programs [EP] on sarcopenia prevention or treatment in children with chronic diseases undergoing Tx.…”

Section: Sarcopenia (Reduced Skeletal Muscle Mass [Mm] Muscle Strengthmentioning

confidence: 99%

“…Sarcopenia (reduced skeletal muscle mass [MM], muscle strength [MS], and physical performance [PP]) has been recently identified in infants and children undergoing solid organ transplantation (Tx) and hematopoietic stem cell transplantation (HSCT) 1–4 . Sarcopenia is associated with adverse perioperative outcomes (prolonged hospitalization and increased ventilator dependency), longer‐term outcomes (delayed growth, reduced survival, increased risk for re‐hospitalization, organ rejection/graft versus host disease) and delayed gross motor function after Tx 3,5–7 . The cause for this condition is multifactorial; related to malnutrition, malabsorption, medications (corticosteroids/chemo or radiotherapy), altered nutrient utilization, reduced growth, and physical activity (PA) 8 .…”

Section: Introductionmentioning

confidence: 99%

Exercise rehabilitation to treat sarcopenia in pediatric transplant populations

Hager,

Guo,

Wang

et al. 2023

Pediatric Transplantation

View full text Add to dashboard Cite

BackgroundIn adult transplant (Tx) populations, exercise rehabilitation strategies may improve sarcopenia components (muscle mass [MM], strength [MS], and physical performance [PP]). Limited data are available regarding exercise rehabilitation therapy in pediatric Tx populations.MethodsThe purpose of this review is to critically evaluate the feasibility and impact of exercise programs (EP) that include resistance exercise (RE) on markers of sarcopenia in pediatric Tx populations. Literature searches in SCOPUS and WEB OF SCIENCE were conducted to identify studies applying EP with a RE component in pediatric populations in the Tx setting.ResultsTwelve articles (2008–2022) met inclusion criteria. The exercise interventions varied in length (3 weeks–12 months), intensity (low to moderate), time pre/post Tx (0 days‐5 years post Tx), age of participants (3–18 years), adherence (63%–94%), and methodologies to measure components of sarcopenia. No studies measured all three components of sarcopenia concurrently. Approximately, 60% of studies found positive effects on MS and PP. Only one pediatric study measured body composition, therefore, the effect of exercise programs with RE components on MM is unknown.ConclusionsExercise programs may be a beneficial treatment for sarcopenia in Tx populations, particularly in components of MS and PP. Studies measuring all three aspects of sarcopenia together in response to RE training in pediatrics remains an important gap. Studies that include body composition measurements in response to exercise are needed. Special considerations for the development of RE programs in pediatrics Tx populations are safety, supervision, engagement through family/peer involvement and incorporation of game/play‐based elements.

show abstract

“…Patients who undergo intensive chemotherapy are at a high risk of malnutrition 4,5 . Various retrospective studies have reported the impact of pretransplant malnutrition on clinical outcomes after allo-HSCT (Table 1) [6][7][8][9][10][11][12][13] . Furthermore, poor performance status during allo-HSCT is a well-established adverse prognostic factor 14,15 .…”

Section: Pre-transplant Nutritional Supportmentioning

confidence: 99%

Nutritional support in allogeneic hematopoietic stem cell transplantation Asian perspective

Fuji

Cheng

Yakushijin

et al. 2022

BCT

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an integral part of the treatment strategy for patients with malignant or non-malignant hematological diseases. Clinical outcomes of patients undergoing allo-HSCT have significantly improved in recent decades. However, transplant-related morbidity and mortality remain major issues for allo-HSCT recipients.With regard to nutrition, patients undergoing allo-HSCT are at high risk for malnutrition. It is expected that clinical practice concerning nutritional support in allo-HSCT has been improving in recent decades; however, no data directly support this expectation. One major issue in managing nutritional support during allo-HSCT is the lack of large-scale randomized prospective studies, which leads to a lack of well-established strategies. Accordingly, we need to gather data from studies in non-HSCT and allo-HSCT settings. In some Asia-Pacific countries, a physician's lack of knowledge of nutritional support may impede the application of nutritional support practices recommended by existing guidelines. Another barrier may be the lack of access to an adequately qualified or trained registered dietitian (RD) at allo-HSCT units. Adequate training in the nutritional management of allo-HSCT patients should be provided to all RDs working with HSCT. Herein, we summarize the information on nutritional support in allo-HSCT, focusing on an Asian perspective.

show abstract

Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study

Cited by 23 publications

References 28 publications

Lower Body Mass Index and Prognostic Nutritional Index Are Associated with Poor Posttransplant Outcomes in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Lower Body Mass Index and Prognostic Nutritional Index Are Associated with Poor Posttransplant Outcomes in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Exercise rehabilitation to treat sarcopenia in pediatric transplant populations

Nutritional support in allogeneic hematopoietic stem cell transplantation Asian perspective

Contact Info

Product

Resources

About